Patent ID: 8273716

Claim:
A method for treating a prostate cancer, the method comprising: administering at least one LHRH antagonist to a subject in need thereof in an amount sufficient to treat the prostate cancer and in a dose which does not cause a chemical or hormonal castration, wherein the at least one LHRH antagonist is a tetrahydrocarbazole derivative with the formula wherein V and W are each independently O, S, S + —O − , or geminally linked H 2 ; R 1 is O, S, or S + —O − ; R 2 is an optionally substituted cycloalkyl, cycloalkylakyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, or —NHX1, wherein X1 is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R 2 or X1 is optionally substituted with —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 ; R 4m is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R 4m is optionally substituted with —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 ; R 8 is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R 8 is optionally substituted with —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 ; R 10 is an optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or —C(O)X1004, wherein X1004 is an optionally substituted cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, and wherein R 10 or X1004 is optionally substituted with —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 ; and R 17 , R 18 , R 10 , and R 20 are each independently —H, —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 .